Skip to main content
Premium Trial:

Request an Annual Quote

Ciphergen, Pfizer Hunt for Markers Linked to Pulmonary Disease

SAN FRANCISCO, Jan. 27 - Ciphergen Biosystems said today it expanded its relationship with Pfizer to conduct protein biomarker studies.


Ciphergen will work with Pfizer in a hunt for markers from human serum for early detection of chronic obstructive pulmonary disease, according to Ciphergen. The studies will take place at Ciphergen's BiomarkerDiscoveryCenterin Copenhagen. The deal is with Pfizer's experimental medicine group in France.


Financial details of the agreement were not disclosed.


In 2001, Ciphergen and Pfizer began a study to look for biomarkers associated with drug safety.


The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.